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Abstract
Synapsin I is a phosphoprotein that coats the cytoplasmic side of synaptic vesicles and regulates their trafﬁcking within
nerve terminals. Autoantibodies against Syn I have been described in sera and cerebrospinal ﬂuids of patients with
numerous neurological diseases, including limbic encephalitis and clinically isolated syndrome; however, the effects
and fate of autoantibodies in neurons are still unexplored. We found that in vitro exposure of primary hippocampal
neurons to patient’s autoantibodies to SynI decreased the density of excitatory and inhibitory synapses and impaired
both glutamatergic and GABAergic synaptic transmission. These effects were reproduced with a puriﬁed SynI antibody
and completely absent in SynI knockout neurons. Autoantibodies to SynI are internalized by FcγII/III-mediated
endocytosis, interact with endogenous SynI, and promote its sequestration and intracellular aggregation. Neurons
exposed to human autoantibodies to SynI display a reduced density of SVs, mimicking the SynI loss-of-function
phenotype. Our data indicate that autoantibodies to intracellular antigens such as SynI can reach and inactivate their
targets and suggest that an antibody-mediated synaptic dysfunction may contribute to the evolution and progression
of autoimmune-mediated neurological diseases positive for SynI autoantibodies.
Introduction
A large battery of autoantibodies directed to neuronal
proteins have been discovered in sera and CSF of patients
suffering from a variety of neurological diseases1. These
autoantibodies target two main classes of antigens,
namely cell surface and intracellular antigens. Auto-
antibodies directed against the amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptors (AMPARs),
the N-methyl-D-aspartate receptor (NMDAR) and the γ-
aminobutyric acid (GABA) type B receptor belong to the
ﬁrst group and are frequently detected in the serum and
cerebrospinal ﬂuid (CSF) of affected subjects2. A number
of studies have clearly demonstrated the direct pathogenic
role of these autoantibodies. Of note, antibody removal
and immunotherapy are effective treatments and promote
a clinical improvement in the affected patients. In con-
trast, the pathogenic role of antibodies directed against
intracellular antigens, such as anti-neuronal nuclear
antibody type 1 (ANNA-1), glutamic acid decarboxylase
(GAD65) and amphiphysin, remains a topic of debate2.
Although evidence exists that antibodies to GAD65 and
amphiphysin have pathogenic effects, a clear mechanism
for antibody internalization and interaction with intra-
cellular targets is still lacking3–7.
A new member of the continuously growing list of
target autoantigens of anti-neuronal antibodies is the SV-
associated protein Synapsin I (SynI). Synapsin I is a
phosphoprotein that coats the cytoplasmic side of SVs
and plays multiple roles in the regulation of SV trafﬁcking
between the RP and the readily releasable pool (RRP) and
in the facilitation of the post-docking steps of release8.
Nonsense and missense mutations in the gene encoding
SynI have been associated with epilepsy, autism spectrum
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disorder (ASD) and intellectual disability in humans9–12.
SynI autoantibodies have been identiﬁed in serum and
CSF from patients suffering of various neurological dis-
orders, including limbic encephalitis, multiple sclerosis,
epilepsy, anxiety, depressive and bipolar disorders, but not
in healthy controls13,14. However, no studies correlating
the effect of these antibodies to the brain pathology have
been published to date.
In the present study, we sought to investigate whether
autoimmune mechanisms involving SynI autoantibodies
inﬂuence the properties of synaptic transmission and
whether a direct interaction between autoantibodies and
the intracellular synaptic target occurs within nerve
terminals. Using patient CSF and puriﬁed antibodies, we
found that anti-SynI antibodies induced marked effects
on neuronal network connectivity and activity including
a decreased density of synaptic connections and an
impairment of excitatory and inhibitory transmission.
We revealed that internalization of anti-SynI antibodies
into neurons occurs through a clathrin-mediated endo-
cytic pathway via Fcγ II/III receptors, followed by
interaction with the cytosolic antigen and change in SV
density and clustering within nerve terminals. Interest-
ingly all these effects phenocopy the SynI knockout (KO)
phenotype and are occluded in SynI KO neurons. Our
ﬁndings provide new insights into a unique immune-
neuronal interaction and indicate a potential pathogenic
role of SynI autoantibodies in promoting “autoimmune
synaptopathies”.
Results
SynI autoantibodies from patient CSF impair excitatory
and inhibitory synaptic transmission in hippocampal
neurons
To investigate potential pathogenic effects of SynI
autoantibodies, we treated primary neurons with the CSF
of a limbic encephalitis and clinical isolated syndrome
patients (herein referred to as LE-CSF and CIS-CSF,
respectively) that were characterized by high titers of IgG
and IgA autoantibodies against SynI13,14. As control, we
pooled CSF from two patients with non-inﬂammatory
neurological disorders that were negative for anti-
neuronal autoantibodies (herein referred to as control
CSF). The demographic and clinical data are reported in
Supplementary Table 113,15. To rule out the possibility
that human CSF per se may induce changes in synaptic
transmission in primary neurons, we compared frequency
and amplitude of mEPSCs and mIPSCs in untreated
neurons, or in neurons treated daily for 3 days with
control CSF or commercial human IgG/IgA antibodies.
None of the experimental conditions induced any change
in the electrophysiological parameters (data not shown).
Accordingly, treatment with control CSF was used as
control condition throughout the study.
We ﬁrst addressed the effect of both LE-CSF and CIS-
CSF treatments on excitatory synaptic transmission by
recording mEPSCs in dissociated hippocampal neurons
at 14 DIV after 72 h of incubation. Under this condition,
the mEPSC frequency was signiﬁcantly reduced in
patient CSF-treated neurons as compared to control CSF
and, consistently, the cumulative probability plots
of inter-event intervals were shifted to greater values
(Fig. 1a, b). mEPSC amplitudes and their the cumulative
probability plot were also signiﬁcantly decreased in
neurons treated with LE-CSF and CIS-CSF (Fig. 1c), in
the absence of changes in the rise and decay times (Fig.
1d). Next, we assessed inhibitory synaptic transmission
by recording mIPSCs. Similar to excitatory transmission,
we found a signiﬁcant reduction in both mIPSC fre-
quency and amplitude of in patient CSF-treated neurons
compared to treatment with control CSF (Fig. 1e–g), in
the absence of changes in the current kinetics (Fig. 1h).
To exclude the possibility that the impairment of
synaptic transmission was due to a nonspeciﬁc cytotoxic
effect of the CSF, resting membrane potential, a very
sensitive index of neuronal health, was measured by
patch-clamp in the current-clamp conﬁguration. No
change in membrane potential was detected in neurons
exposed to both LE-CSF and CIS-CSF as compared to
control CSF-treated neurons, suggesting that neurons are
healthy and viable (resting potential mV, mean ± SEM:
control CSF −56,86 ± 1,57; LE-CSF −56.00 ± 1.05; CIS-
CSF −51.33 ± 1635).
The consistent decrease in the frequency of sponta-
neous synaptic events of both excitatory and inhibitory
transmission suggests that a possible loss of synaptic
connection might have occurred during exposure to the
patient-CSF. Indeed, double labeling with β-tubulin and
either the glutamatergic or GABAergic SV markers
VGLUT1 and VGAT demonstrated a signiﬁcant decrease
in the density of both excitatory and inhibitory synaptic
puncta in cultures exposed to LE-CSF compared to con-
trol (Fig. 1i–j). Consistently, presynaptic labeling of both
excitatory and inhibitory terminals with antibodies to SynI
revealed a signiﬁcant decrease of the SynI-positive puncta
after LE-CSF treatment (Fig. 1i–j).
The pathophysiological effects of patient’s CSF are
speciﬁcally due to anti-SynI antibodies
To unambiguously demonstrate that the physiological
effects were causally linked to SynI autoantibodies, we
used afﬁnity-puriﬁed anti-SynI monoclonal IgGs (SynI-
mAb). Interestingly, treatments with SynI-mAb induced a
signiﬁcant reduction in the frequency and amplitude of
both mEPSCs and mIPSCs compared to control condi-
tions (Fig. 2a, b), fully mimicking the results obtained with
either LE-CSF or CIS-CSF (Fig. 1). These ﬁnding suggest
that the impairment of excitatory and inhibitory synaptic
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transmission is speciﬁcally mediated by the auto-
antibodies to SynI.
The expression of endogenous SynI is required for limbic
encephalitis CSF-induced effects on synaptic transmission
Although SynI is an intracellular antigen that never gets
exposed on the cell surface in healthy neurons, we asked
whether the effects of CSF containing SynI autoantibodies
could be mediated by the interaction of autoantibodies
with endogenously expressed SynI protein. To test this
hypothesis, we repeated the above experiments by
exposing SynI KO neurons to patient CSF and evaluating
the effect on excitatory and inhibitory synaptic trans-
mission. Unlike wild type neurons, SynI KO hippocampal
cultures did not show any difference in frequency,
amplitude and kinetics of both mEPSCs (Fig. 3a–d) and
mIPSCs (Fig. 3e–h) when treated with either LE or con-
trol CSF. Consistent with these ﬁndings, there was no
difference in the density of both excitatory and inhibitory
synapses in SynI KO hippocampal neurons treated with
LE-CSF with respect to those treated with control CSF
(Fig. 3i, j). Altogether, these results indicate that patient
CSF-induced dysregulation in primary neurons strictly
targets the endogenous SynI protein.
Internalization of SynI antibodies is mediated by clathrin-
dependent endocytosis via Fc II/III receptors
To detail the mechanism responsible for SynI antibody-
mediated effects, we asked whether anti-SynI antibodies
enter neurons. To this aim, cells were treated with either
LE-CSF or SynI-mAb for 72 h, ﬁxed, permeabilized and
immunoreacted with anti-human or anti-mouse second-
ary antibodies, respectively (Fig. 4a). Patient CSF-treated
cells showed an intense immune staining of neuronal
bodies and dendrites compared to control CSF, and an
even stronger staining pattern was observed after incu-
bation with SynI-mAb (Fig. 4a, c). In contrast, SynI KO
neurons showed only a faint background signal under
both conditions (Fig. 4b, c). Consistent with the strict
intracellular location of SynI, no signal was detected
without permeabilization (data not shown;8). The cell
internalization of SynI autoantibodies was conﬁrmed by
ultrastructural analysis of nerve terminals subjected to
pre-embedding immunogold electron microscopy. LE-
CSF treated neurons showed a clear accumulation of gold
particles directed against human IgG antibodies at
synaptic terminals as compared with cultures treated with
control CSF (Fig. 4d, e).
In contrast to autoantibodies directed to membrane-
bound receptors, it has been long discussed whether and
how antibodies against intracellular antigens could reach
their target. Thus, we tested the hypothesis that the
uptake of anti-SynI antibodies was mediated by the
endocytic pathway. Addition of the nonspeciﬁc blocker of
ATP-dependent endocytosis sodium azide16 to neurons
incubated with SynI-mAb induced a signiﬁcant reduction
of the antibody uptake (Fig. 5a, b) and abolished the
effects of both SynI-mAb and LE-CSF treatments on
mEPSC and mIPSC frequency and amplitude (Fig. 5c, d).
To conﬁrm this result using a distinct inhibitor of endo-
cytosis, we pretreated neurons PitStop2, an inhibitor of
clathrin-mediated endocytosis17. We found that PitStop2,
similarly to sodium azide, reduced the internalization of
SynI-mAb (Fig. 5a, b), indicating that the antibody uptake
mainly occurs via clathrin-dependent endocytosis.
Fcγ receptors (FcγRs) are a family of molecules
expressed on the surface of a variety of cells, including
neurons, which bind the Fc region of IgG and are similarly
expressed in both WT and SynI KO neurons18 (Fig. 5e). A
number of studies have shown that the interaction
between autoantibodies and FcγRs has a detrimental role
in neurodegenerative pathologies, including Parkinson’s
and Alzheimer’s diseases19. In particular, it has been
shown that FcγRs can mediate antibody uptake into
neurons via clathrin-mediated endocytosis20. To further
clarify the molecular mechanism responsible for antibody
uptake, we co-incubated hippocampal neurons with SynI-
mAb and increasing concentrations of FcγR II/III
(see ﬁgure on previous page)
Fig. 1 Patient-derived SynI autoantibodies decrease excitatory and inhibitory synaptic transmission and synapses. a Representative
recordings of miniature excitatory postsynaptic currents (mEPSCs) in primary hippocampal neurons treated with either control CSF (1.5 μg/mL, black
traces), LE-CSF (1.5 μg/mL, red traces) or CIS-SF (1.5 μg/mL, blue traces) for 72 h. b Cumulative distribution of inter-event intervals and mean mEPSC
frequency. c Cumulative distribution and mean of mEPSC amplitude. d Rise and decay times of mEPSCs. e Representative recordings of miniature
inhibitory postsynaptic currents (mIPSCs) in hippocampal neurons treated as in (a). f Cumulative distribution of inter-event intervals and mean
frequency of mIPSCs. g Cumulative distribution and mean of mIPSC amplitude. h Rise and decay times of mIPSCs. Cumulative plots show pooled
data from all neurons; graphs show means ± SEM, single neuron data points from at least three independent preparations; *p < 0.05, ***p < 0.001,
Kruskal–Wallis test and Dunn’s post hoc. i Representative images of primary hippocampal neurons treated with either control CSF or LE-CSF (1.5 μg/
mL) for 72 h and stained for β-III tubulin (blue), VGLUT1 (green) and VGAT (red). Scale bars, 10 and 1 μm for low and high magniﬁcation, respectively.
j, k Density of VGLUT1-positive excitatory synapses (j) and VGAT-positive inhibitory synapses (k) in control CSF and LE-CSF treated neurons.
l Representative images of primary hippocampal neurons treated as in (a) and stained for β-III tubulin (blue) and SynI (green). Scale bars, 10 and 1 μm
for low and high magniﬁcation, respectively. m Quantiﬁcation of the density of SynI immunoreactive synaptic puncta. Graphs show means ± SEM,
single neuron data points from three independent preparations; **p < 0.01, ***p < 0.001, Mann–Whitney test.
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receptor blocker anti-CD16/CD32 monoclonal antibody
(α FcγR II/III). The extent of internalization of SynI-mAb,
slightly inhibited by the lowest dose of αFcγR II/III anti-
bodies (0.5 µg/mL), was strongly inhibited at higher con-
centrations of αFcγR II/III antibodies (5 and 10 µg/mL) as
compared to the control condition (absence of α FcγR II/
III antibody) (Fig. 5b, c). Co-treatment with unrelated
isotype-matched anti-His-tag antibody did not affect the
internalization of SynI-mAb (data not shown).
Altogether, these results strongly suggest that SynI-
mAb uptake into neurons occurs via clathrin-dependent
FcγR-mediated endocytosis.
Endocytosed SynI antibodies can escape the endocytic
compartments and target endogenous SynI
To analyze whether the extracellularly applied anti-SynI
antibodies that had been endocytosed are released in the
cytosol, we exposed primary neurons to the SynI-mAb
antibody for 72 h and performed a gentle subcellular
fractionation under isotonic high ionic strength condi-
tions known to dissociate SynI from SVs and maintain the
integrity of intracellular organelles21,22.
Thus, we subjected the post-nuclear supernatant to
high-speed centrifugation to separate membranes, orga-
nelles and cytoskeletal polymers (P3 fraction) from the
soluble cytosolic fraction (S3). Interestingly, a detectable
amount of the antibody was present in the S3 fraction,
testifying that it escaped from the endocytic compartment
(Fig. 6a).
To test whether endocytosed anti-SynI antibodies form
an intracellular complex with endogenous SynI, we
applied two experimental strategies. First, we performed
an immunoprecipitation assay in wild type neurons
extracellularly exposed to the SynI-mAb antibody for
72 h. When the SynI-mAb was quantitatively pulled down
from the cell extract with Protein-G beads, a detectable
amount of endogenous SynI was co-immunoprecipitated,
indicating the formation of an intracellular complex
between the exogenous antibody and SynI (Fig. 6b). Sec-
ond, a physical interaction between the SynI-mAb and
endogenous SynI was detected by the proximity ligation
assay (PLA). WT and SynI KO neurons were treated with
either vehicle or the SynI-mAb antibody for 72. After
ﬁxing, an afﬁnity-puriﬁed rabbit antibody against the N-
terminal domain of SynI, G143, was used to recognize
endogenous SynI. Next, secondary antibodies coupled to
different oligonucleotides (PLA rabbit and PLA mouse
probes) were applied and the ﬂuorescent PLA signal (red
dots) generated by rolling-circle ampliﬁcation was quan-
tiﬁed. SynI-mAb-treated WT neurons showed abundant
PLA dots compare to control conditions, whereas SynI
KO neurons showed only few PLA puncta under both
conditions (Fig. 6c, d). These data demonstrate that
intracellular SynI antibodies physically interact with the
endogenous target.
Release of anti-SynI antibodies in the cytosol impairs SynI-
dependent SV clustering
It was recently demonstrated that SynI undergoes phase
separation and condensate in droplets under physiological
conditions in vitro, suggesting that SynI can guide protein
phase separation required for SV clustering23. To assess
whether exposure to SynI autoantibodies alters the ability
of SynI to undergo phase separation and form droplets,
Fig. 2 The synaptic effects of patient-derived SynI autoantibodies are mimicked by afﬁnity-puriﬁed anti-SynI antibodies. a, b Mean
frequency and amplitude of mEPSCs (a) and mIPSCs (b) in neurons exposed for 72 h to afﬁnity-puriﬁed anti-SynI monoclonal antibodies (Synaptic
System #106011; SynI-mAb, 1.5 μg/mL, red bar), as compared to vehicle (white bar). Graphs show means ± SEM, single neuron data points from three
independent preparations; *p < 0.05, **p < 0.01, ***p < 0.001, Mann–Whitney test.
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we incubated puriﬁed GFP-SynI under conditions
mimicking the intracellular milieu and analyzed the
ﬂuorescence signal by TIRF microscopy. After few min-
utes, GFP-SynI incubated with control CSF formed dro-
plets and the process reached a plateau phase after
45 min, however clear and signiﬁcant increase in droplet
formation was observed after the exposure to patient’s
CSF at both short and long time points (Fig. 7a, b).
If droplet formation reﬂects the state of aggregation of
SynI and acts as sort of decoy mechanism for SynI during
the SV cycle, one would expect a difference in the density
of SVs in nerve terminals of neurons treated with LE-CSF,
mimicking the effect of SynI deletion in mice24.
To ascertain this possibility, we performed an ultra-
structural analysis of nerve terminals by conventional
transmission electron microscopy in patient CSF-treated
neurons. Interestingly, nerve terminals of patient CSF-
treated neurons were depleted of SVs, with a signiﬁcant
reduction in density of SVs compared to control CSF-
treated neurons, in the absence of changes in the AZ-
docked SVs (Fig. 7c, d). This phenotype resembles the
phenotype of SynI KO neurons25–27 and indicates that
SynI autoantibodies sequester endogenous SynI and alter
its ability to form liquid phase and cluster SVs.
Discussion
Antibodies to cell adhesion molecules, neuro-
transmitter receptors, ion channels, proteins related to
synaptogenesis, neurotransmitter synthesis and SV
endocytosis have been identiﬁed in numerous group of
neurological diseases1. Several studies have shown that
antibodies to surface antigens have a clear pathogenic
role in disease development and progression, whereas
straightforward pathogenetic mechanisms are more dif-
ﬁcult to identify for autoantibodies directed to intracel-
lular antigens.
We have recently identiﬁed intrathecally synthesized
IgA/IgG autoantibodies to the SV-associated protein
SynI in several patients suffering from various neu-
ropsychiatric diseases, including limbic encephalitis,
multiple sclerosis, depression, anxiety, and bipolar
disorders13,14,23. SynI is a SV phosphoprotein playing
multiple roles in synaptic transmission and plasticity. It
participates in synapse formation and maintenance,
plays a major role in clustering SVs creating a RP of SVs
and regulating their availability for exocytosis, and dif-
ferentially affects the post-docking steps of release in
excitatory and inhibitory synapses8. It is currently
believed that its action in the assembly of the SV RP
occurs through oligomerization of Syn molecules that
cross-link SVs and bind them to the actin cytoskele-
ton28–32. Moreover, it was recently reported that SynI-
induced phase separation in the cytoplasm of the nerve
terminal restricts the formation of SV clusters in the
proximity to presynaptic release sites23,33.
In this study, we provide evidence that human SynI
autoantibodies can adversely contribute to synaptic dys-
function. Firstly, these antibodies alter excitatory and
inhibitory synaptic transmission in cultured hippocampal
neurons and decrease the levels of SynI-positive synaptic
contacts. The effects are highly speciﬁc for SynI, as SynI
KO neurons incubated with patient-derived CSF did not
show any change in synaptic transmission. Moreover, an
identical synaptic phenotype was observed using afﬁnity-
puriﬁed anti-SynI antibodies. The observed phenotype
conﬁrms the role of SynI in the formation and main-
tenance of synaptic connections, as well as in adjusting
the number of synaptic connections in response to
extracellular signals34,35
Secondly, these antibodies are internalized by a clathrin-
dependent endocytosis mediated by FcγII/III receptors,
which bind the constant region of IgG and are highly
expressed in neurons. These ﬁndings are consistent with a
general role of FcγRs in antibody uptake, as previously
shown for anti-Tau antibody internalization in a mouse
model of Alzheimer’s disease and for IgGs from amyo-
trophic lateral sclerosis patient in spinal cord motor
neurons20,36. The neuronal uptake of the antibodies and
the emergence neuronal phenotype are causally related,
since inactivation of distinct mechanisms of endocytosis
or neutralization of FcγRs largely abolished both the
antibody uptake and the synaptopathy. Interestingly, no
(see ﬁgure on previous page)
Fig. 3 The effects of LE-derived SynI autoantibodies on excitatory and inhibitory transmission and synapses are abolished in SynI KO
hippocampal neurons. a Representative recordings of mEPSCs in SynI KO hippocampal neurons treated with either control CSF (1.5 μg/mL, black
trace) or LE-CSF (1.5 μg/mL, green trace) for 72 h. b–d Cumulative distribution of inter-event intervals and mean frequency of mEPSCs (b), cumulative
distribution and mean of mEPSC amplitude (c) and rise/decay times of mEPSCs (d). e Representative recordings of mIPSCs in SynI KO hippocampal
neurons treated as described in (a). f–h Cumulative distribution of inter-event intervals and mean frequency of mIPSCs (f), cumulative distribution
and mean of mIPSC amplitude (g) and rise/decay times of mIPSCs (h). Graphs show means ± SEM, single neuron data points from four independent
preparations; not signiﬁcant, two-tailed Student’s t-test. i Representative images of primary SynI KO hippocampal neurons treated with either control
CSF or LE- CSF (1.5 μg/mL) for 72 h and stained for β-III tubulin (blue), VGLUT1 (green), and VGAT (red). Scale bars, 10 and 1 μm for low and high
magniﬁcation, respectively. j Density of VGLUT1- positive excitatory synapses (upper panel) and VGAT-positive inhibitory synapses (lower panel) in
control and patient CSF-treated SynI KO neurons. Cumulative plots show pooled data from all neurons; graphs show means ± SEM, single neuron
data points from three independent preparations; not signiﬁcant, two-tailed Student’s t-test.
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Fig. 4 Patient autoantibodies and afﬁnity-puriﬁed SynI antibodies have a similar distribution in primary neurons and their intracellular
accumulation requires SynI. Representative images of WT (a) or SynI KO (b) neurons incubated for 72 h with either LE-CSF, SynI-mAb or equal
volumes of the respective vehicles. Neurons were ﬁxed and primary antibodies were visualized with anti-human and anti-mouse ﬂuorescently
conjugated secondary antibodies (green), respectively. Double staining for βIII tubulin (blue) was performed after ﬁxation. Scale bars, 10 and 1 μm for
low and high magniﬁcation, respectively. c Quantiﬁcation of the intensity of primary antibody immunoreactivity. The graph shows means ± SEM,
single neuron data points from 4 independent preparations; ***p < 0.001, two-way ANOVA/Bonferroni’s tests. d Representative TEM images of nerve
terminals from cultured hippocampal neurons incubated with either control CSF or LE-CSF and processed for immunogold against human IgG
antibody. Arrow indicates gold particles after gold enhancement. Scale bars, 200 nm. e Histograms representing the percentage of gold-positive
synapses. Graphs show means ± SEM, n= 4–5 synapses from two independent preparations; *p < 0.05, two-tailed Student’s t-test.
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antibody accumulation was observed in SynI KO neurons.
We speculate that antibody uptake is equally efﬁcient in
both genotypes, but that, once internalized into SynI KO
neurons, SynI autoantibodies cannot bind the endogenous
target and are therefore more prone to degradation. Once
internalized, the exogenous antibodies escape the endo-
cytic compartment and accumulate in the cytosol, where
they bind endogenous SynI, as demonstrated by sub-
cellular fractionation, immunoprecipitation and in situ
PLA assays.
Recent studies have shown liquid–liquid phase separa-
tion is a mechanism through which intracellular compo-
nents can assemble into membrane-lacking
compartments33,37–40 and that SynI, present in high
concentrations within nerve terminals, can undergo phase
separation leading to SV clustering23. Indeed, we found
that the formation of a SynI/antibody complex after
incubation with patient CSF increases droplet formation,
reﬂecting an excessive SynI aggregation/sequestration
that may impair clustering of SynI and induce their dis-
persion in the cytosol. Notably, treatment of neurons with
patient CSF induced a synaptic phenotype characterized
by decreased overall SV density with no change in the
number of docked SVs that fully mimics the phenotype of
SynI KO mice25–27. These results are consistent with the
hypothesis that anti-SynI antibodies determine a loss-of-
function effect in primary neurons and also agree with the
dramatic loss of SV clusters following injection of anti-
SynI antibodies in giant reticulo-spinal axons of the
lamprey41.
In the diseases associated with GAD65 and amphiphy-
sin autoantibodies, several ﬁndings have shown the
pathogenic role of the autoantibodies3–5. Since both
intracellular antigens are involved in the SV exo-
endocytotic cycle, one possibility is that they get tran-
siently exposed to the extracellular environment during
synaptic activity. This model could also account for SynI
antibody uptake. Such a mechanism has been proposed
for the nerve terminal uptake of Botulinum neurotoxins
that bind to the intraluminal domains of the integral SV
proteins SV2 and synaptotagmin that become exposed
during exocytosis42. However SynI, similarly to GAD and
amphiphysin, is not an integral membrane protein and
coats the cytosolic side of the SV membrane, so that it
should never get exposed to the extracellular space during
the SV cycle. Although the highly hydrophobic C domain
of SynI partially penetrates the hydrophobic core of the
SV membrane, it is highly unlikely that it can cross the
whole membrane thickness22,43. In addition, the SynI
autoantibodies found in limbic encephalitis and clinically
isolated syndrome patients are directed to the hydrophilic
and highly immunogenic COOH-terminal domain that
has a permanent cytosolic exposure15. It is noteworthy to
mention that the SynI COOH-terminal D-domain, target
of epileptogenic mutations in humans9,44, plays a key role
in SynI function: it participates in dimerization and hosts
two CaM kinase II sites, whose phosphorylation regulates
SynI binding to actin and SVs, as well as its phase
separation properties15,23,31,45.
The etiology and pathogenesis of autoantibody-
mediated brain diseases is only partially understood, as
far as the antibody production trigger in the non-
paraneoplastic cases and the antibody effects are con-
cerned. It is possible that the intrathecal production of
SynI autoantibodies is triggered by neuronal damage or by
extracellular release of SV-bound SynI via exosomes
under conditions of high neuronal activity or oxidative
stress46. While their presence may be an epiphenomenon
of cell damage induced by the underlying neuronal
pathology, the secondary production of SynI auto-
antibodies can play a role in disease progression and
pleiotropy clinical symptoms (see refs. 47,48 for review).
Our work has the limitation of a small number of human
samples and this frequently occurs in the earliest
description of new clinical ﬁndings. However, our report
provides a ﬁrst proof of principle for the detrimental
effects of anti-SynI antibodies in autoimmune diseases
and may provide new insights in other forms of
(see ﬁgure on previous page)
Fig. 5 Blockade of clathrin-mediated endocytic pathway via Fc II/III receptors inhibits SynI antibody uptake and restores synaptic
transmission. a Representative images of SynI-mAb (1.5 μg/mL)-treated hippocampal neurons incubated either with sodium azide (NaN3; 500 nM),
PitStop 2 (30 μM) or α FcγR II/III antibody at the indicated concentrations for 72 h. The control condition indicates cells exposed to SynI-mAb in the
presence of the NaN3/PitStop2 solvent. After treatments, cells were ﬁxed, permeabilized and incubated with anti-mouse ﬂuorescent secondary
antibodies (green). Double staining for βIII-tubulin (blue) was performed after ﬁxation. Scale bars, 10 μm. b Quantiﬁcation of the immunoreactivity
intensity of internalized SynI-mAb. Graph shows mean ± SEM, single neuron data points independent preparations; **p < 0.01, ***p < 0.001, one-way
ANOVA/Dunnett’s tests versus control. c Mean frequency and amplitude of mEPSCs (upper panels) and mIPSCs (lower panels) in hippocampal
neurons treated with either SynI-mAb (1.5 μg/mL) or vehicle for 72 h in the presence or absence of 500 nM NaN3. d Mean frequency and amplitude
of mEPSCs (upper panels) and mIPSCs (lower panels) in hippocampal neurons treated with either control CSF or patient #1 CSF (1.5 μg/mL) for 72 h in
the presence or absence of 500 nM NaN3. Graphs show means ± SEM, single neuron data points from three independent preparations;
*p <0.05, **p < 0.01, two-way ANOVA/Bonferroni’s tests. e Expression of FcγII/III receptors in WT and SynI KO hippocampal neurons. Representative
images of primary WT and SynI KO hippocampal neurons at 14.
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Fig. 6 Endocytosed SynI antibodies escape the endocytic compartments and target endogenous SynI. a Hippocampal neurons, incubated
daily for three days with either SynI-mAb (1.5 μg/mL) or vehicle, were subjected to subcellular fractionation to obtain the post-nuclear supernatant
(S1), a cytosolic fraction (S3) and a membrane-enriched fraction (P3). A representative immunoblot with anti-SynI (SynI), anti-synaptophysin (Syp),
anti-β-tubulin III (βIII Tub), and anti-mouse secondary antibodies (anti-IgG) to test the presence of the internalized SynI-mAb is shown.
b Immunoprecipitation (IP) of the complex between internalized SynI antibodies and endogenous SynI was performed in hippocampal neuronal
extracts with Protein G-Sepharose after incubation of neurons with either SynI-mAb or vehicle for 24 h. Equal aliquots of the starting material (input)
and of the supernatants (SUP) together with the IP samples were subjected to western blotting with anti-SynI antibodies (SynI) and anti-mouse
secondary antibodies (anti-IgG) to test the recovery of the internalized SynI antibodies. Left: A representative immunoblot is shown. Right:
quantiﬁcation of the SynI immunoreactivity signal in the immunoprecipitated samples, normalized to the binding in the control sample (means ±
SEM, n= 3 independent experiments). Input, 20 μg cell extract. ***p < 0.001, two-tailed Student’s t-test. c Representative confocal images of in situ
proximity ligation assay (PLA) in WT and SynI KO hippocampal neurons incubated with either SynI-mAb (1.5 μg/mL) or vehicle for 72 h. After ﬁxation,
cells were stained with Syn I G143 antibody and processed to detect SynI-mAb and synapsin I proximity interactions. Positive interactions are
indicated as red dots. DAPI-stained nuclei are indicated in blue. Scale bars, 5 μm. d Quantiﬁcation of the number of PLA spots. Graphs show means ±
SEM, single neuron data points from three independent preparations; *p < 0.05, **p < 0.01, two-way ANOVA/Bonferroni’s tests.
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CSF samples were obtained by lumbar punctures, which
were performed for diagnostic purposes only and with the
patients’ written informed consent. Following routine
diagnostic work-up, remaining CSF was stored at −20 °C.
The study was approved by the Institutional Review Board
of Charité - Universitätsmedizin Berlin (EA1/083/15 and
EA1/182/10) and participants provided written informed
consent. Demographics and clinical features of the
patients included in this work are summarized in Sup-
plementary Table S1.
Preparation of primary neurons
Primary hippocampal cultures were prepared from wild
type C57Bl/6J mice (Charles River, Calco, Italy) and SynI
KO mice extensively backcrossed in the C57Bl/6J back-
ground, as previously described10. All experiments were
carried out in accordance with the guidelines established
by the European Community Council (Directive 2010/63/
EU of 22 September 2010) and were approved by the
Italian Ministry of Health. For experiments involving
treatments with human CSF (indicated as LE-CSF for
limbic encephalitis patient, SM-CSF for multiple sclerosis
patient and control CSF for healthy patients) and afﬁnity-
puriﬁed SynI antibody (SynI-mAb, monoclonal mouse
anti-Synapsin I antibody directed against the SynI
435–475 peptide in the D domain of SynI; #106011,
Synaptic System, Germany), cultures were treated daily
for 3 days (11–14 DIV) with a medium containing either
1.5 μg IgG/mL CSF or SynI-mAb antibody. As a control
for the treatment with SynI-mAb, cultures were subjected
to the same medium change with addition of an equiva-
lent volume of vehicle. For the experiments aimed at
determining the role of endocytosis on SynI antibody
internalization, 500 nM sodium azide (NaN3; Sigma-
Aldrich, Milano, Italy), 30 µM Pitstop2 (Abcam, Cam-
bridge, MA), CD16/CD32 rabbit monoclonal antibody
(clone 2.4G2, ABS410, Enzo LifeScience, New York, NY)
or 6X His-tag rat monoclonal antibody (ab206504,
Abcam) was added 30min before the treatments.
Patch-clamp electrophysiology
Primary mouse hippocampal neurons incubated under
the various conditions were used for patch-clamp
recordings at 14 DIV as previously described49. Minia-
ture PSCs (mPSCs) were acquired at 10 to 20 kHz sample
frequency, ﬁltered at half the acquisition rate with an 8-
pole low-pass Bessel ﬁlter, and analyzed by using the
Minianalysis program (Synaptosoft, Leonia, NJ). Ampli-
tude and frequency of mPSCs were calculated using a
peak detector function using different appropriate
threshold amplitude and area. All parameters were ana-
lyzed using pClamp (Molecular Devices) and Prism7
(GraphPad Software, Inc.) software.
Immunoﬂuorescence
Hippocampal neurons were stained as described50. The
primary antibodies used were anti-Synapsin I (clone
10.22, Millipore, USA), anti-vesicular glutamate
transporter-1 (VGLUT1, AB5905, Millipore), anti-
vesicular GABA transporter (VGAT, 131 011, Synaptic
System), anti-β-tubulin III (T2200, Sigma-Aldrich), anti-
green ﬂuorescent protein (GFP, 11814460001, Sigma-
Aldrich), anti-FcγRII/III (clone 2.4G2, ABS410, Enzo
LifeScience). Incubation with primary antibodies (patient/
control CSF and SynI-mAb) to visualize anti-SynI anti-
body internalization was performed in live neurons. After
the primary incubation, neurons were incubated for
45min with secondary antibodies in blocking buffer.
Fluorescently conjugated secondary antibodies were from
Molecular Probes (Thermo-Fischer Scientiﬁc). Image
acquisitions were performed using a confocal microscope
(SP8, Leica Microsystems, Wetzlar, Germany) at ×63 (1.4
NA) magniﬁcation. Z-stacks were acquired every 300 nm,
10 ﬁelds/sample. SynI, VGLUT and VGAT ﬂuorescence
intensity values were normalized to the relative cell
volume calculated on the basis of βIII-tubulin labeling.
The analysis was conducted using ImageJ software (ver.
1.51 k). For each set of experiments, all images were
acquired using identical exposure settings.
(see ﬁgure on previous page)
Fig. 7 The interaction between internalized SynI antibodies and SynI decreases SV density and increases SynI liquid phase separation. a, b
Representative images (a) and frequency distribution (b) of GFP-SynI droplets incubated with either control CSF or LE-CSF (25 μg/ml) for 5 and
45min. Scale bars, 10 and 0.05 μm for low and high magniﬁcation, respectively. Each condition was assessed by two independent incubations.
c Representative micrograph showing synapses from primary hippocampal neurons incubated with either control CSF or LE-CSF (1,5 μg/ml) for 72 h.
Scale bar, 300 nm. d Upper panels: Quantiﬁcation of SV and docked SV density in the analyzed terminals. Lower panel: quantiﬁcation of the spatial
distribution of SVs from active zone (AZ). Graphs show means ± SEM, single neuron data points from three independent preparations **p < 0.01,
Mann–Whitney test.
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Transmission electron microscopy
Primary hippocampal neurons were processed as
described previously10. For each experimental condition,
at least 30 images of synapses were acquired at 10,000x
magniﬁcation (sampled area per experimental condition:
36 μm2). Synaptic morphological features, including nerve
terminal area, active zone (AZ) length, number and den-
sity of total and AZ-docked SVs, distance from the AZ,
number and density of gold particles were determined
using ImageJ software (ver. 1.51 k). SVs were deﬁned as
vesicles with a diameter of 40–50 nm.
Subcellular fractionation and immunoprecipitation assays
Hippocampal neurons were treated daily for 3 days
(11–14 DIV) with 1.5 µg/mL SynI-mAb in cell medium
and subjected to biochemical fractionation. Cells were
homogenized in PBS/200 mM NaCl supplemented with
1 mM phenylmethylsulfonyl ﬂuoride (PMSF)/1 mM pep-
statin (Sigma-Aldrich), incubated for 1 h on ice and
cleared by low-speed centrifugation (10 min at 10,000 × g
at 4 °C). The post-nuclear supernatant (S1) was cen-
trifuged at 95,000 rpm for 1 h (Beckman TLA 100.2 rotor)
to obtain a cytosolic fraction (S3) and a membrane-
enriched fraction (P3). For immunoprecipitation assays,
neurons, incubated with 1.5 µg/mL SynI-mAb for 72 h in
cell medium, were lysed in lysis buffer (150 mM NaCl,
50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1% Triton X-100)
supplemented with 1 mM PMSF/1 mM pepstatin. After
10 min incubation on ice, lysates were collected and
clariﬁed by centrifugation (10 min at 10,000 × g at 4 °C).
Equivalent amounts of cell extract (500 µg) were incu-
bated for 2 h at 4 °C with Protein G-Sepharose (GE
Healthcare) and the samples were then extensively
washed in lysis buffer. Protein concentration of the sam-
ples was determined by the Bradford Assay (Bio-Rad) and
equivalent amounts of protein were subjected to SDS-
PAGE and western blotting with the following primary
antibodies: rabbit anti-SynI (5297, Cell Signaling), rabbit
anti-synaptophysin (10101, Synaptic System), rabbit anti-
β-tubulin III (T2200, Sigma-Aldrich) followed by
peroxidase-conjugated goat anti-rabbit secondary anti-
bodies (Bio-Rad, USA). The presence and efﬁcient immu-
noprecipitation of SynI-mAb was directly revealed by
incubation of the nitrocellulose membrane with
peroxidase-conjugated goat anti-mouse secondary anti-
bodies (Bio-Rad). Bands were revealed with the ECL che-
miluminescence detection system (Thermo Scientiﬁc) and
quantiﬁed by densitometric analysis of the ﬂuorograms.
Indirect proximity ligation assay (PLA)
The in situ PLA was performed on WT and SynI KO
neurons treated daily for 3 days (11–14 DIV) with a
medium containing either 1.5 μg SynI-mAb antibody or
vehicle. Cells were ﬁxed PBS-4% paraformaldehyde for
15min at room temperature (RT), permeabilized with
0.1% Triton X-100 for 5 min. DuoLink PLA technology
probes and reagents (DUO92008, Sigma-Aldrich) were
used as described51. Two afﬁnity-puriﬁed rabbit anti-
bodies against SynI were used to recognize endogenous
SynI: SynI G143 (directed against the SynI 3–13 peptide
in the A domain52; SynI G115 (directed against the SynI
587–609 peptide in the D domain of SynI45. Coverslips
were mounted with Duolink mounting media with DAPI.
Proximity ligation assay imaging was performed within
6 h using a confocal microscope (SP8, Leica Micro-
systems) at 63× (1.4 NA) magniﬁcation. The number of
puncta per image was calculated using ImageJ (ver. 1.51 k).
For each set of experiments, all images were acquired
using identical exposure settings.
GFP-SynI protein expression and puriﬁcation
The expression vector for GFP-tagged rat SynI (a-iso-
form; GFP-SynI) was kindly donated by H.-T. Kao (Brown
University, Providence, RI). GFP-Syn I was expressed in
HEK293T cells using calcium phosphate (40 μg GFP-SynI
for 3.5 × 106 cells/150 mm dish). HEK293T cells were
routinely cultured in IMDM (Sigma-Aldrich), supple-
mented with 100 units/ml penicillin, 100 μg/ml strepto-
mycin, glutamine, and 10% heat-inactivated FCS (Life
Technologies). HEK293T cells were lysed in buffer that
contained 25 mM Tris-HCl (pH 7.4), 300 mM NaCl,
0.5 mM Tris-2-carboxyethyl-phosphine hydrochloride
(TCEP), and protease inhibitors (1 mM PMSF/1 mM
pepstatin; Sigma-Aldrich). The lysate was centrifuged for
1 h at 17,000 g, followed by afﬁnity puriﬁcation of GFP-
SynI using GFP-Trap A (Chromotek, Germany) for 2 h.
After extensive washes in washing buffer (25 mM Tris-
HCl (pH 7.4), 150mM NaCl, 0.5 mM TCEP), bound
proteins were eluted by 250 μL of 0.2M glycine pH 2.5
followed by 30 s incubation under constant mixing and
centrifugation. The supernatant was immediately neu-
tralized by adding 25 μL of Tris-base (pH 10.4) and stored
at −80 °C until use.
Total internal reﬂection ﬂuorescence microscopy
Droplets of GFP-SynI (1 μM) were prepared in 25mM
Tris-HCl (pH 7.4), 150mM NaCl, 0.5 mM TCEP, 3% PEG
8000 (Fluka Chemicals) in a ﬁnal volume of 100 μl.
Control CSF, patient CSF or water, in volumes equivalent
to 3 μg patient’s IgG, was added to a ﬁnal volume of
120 μL. For total internal reﬂection ﬂuorescence micro-
scopy (TIRFM), the ﬁnal mixture was immediately
pipetted on 35mm-glass bottom dishes (P35G-0-14-C,
MatTek Corp, USA) pre-coated with poly-L-lysine (1 mg/
ml, Sigma). TIRFM images were acquired at RT using
AF6000LX/TIRF MC at ×100 magniﬁcation (PL FLUO-
TAR HCX N.A. 1.30-0.60 OIL 1.4 NA) (Leica) and pro-
cessed using Image J software (ver. 1.51 k).
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Data analysis
Results are presented as means ± SEM. All experiments
were independently performed at least twice. No statis-
tical methods were used to determine the sample size for
experiments. Outliers were determined via Grubb’s test.
Normal distribution of data were assessed using the
Kolmogorov−Smirnov test. The two-tailed unpaired
Student’s t-test was used to compare two normally dis-
tributed sample groups, while either one- or two-way
ANOVA followed by Bonferroni’s multiple comparison
test was used to compare more than two normally dis-
tributed sample groups. For datasets of non-normal dis-
tribution, Mann–Whitney test or Kruskal–Wallis and
Dunn’s post hoc comparison were used. A p < 0.05 was
considered signiﬁcant. Statistical analysis was carried out
using SigmaStat 13 (Systat Software).
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